Linsitinib
Linsitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against insulin-like growth factor 1 receptor. In addition, it is known to target insulin receptor and insulin receptor-related protein.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 3 | 1 | — | — | 4 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 2 | 2 | — | — | 2 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | 2 | 2 | — | — | 2 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 2 | 2 | — | — | 2 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | 2 | 2 | — | — | 2 |
| Exophthalmos | D005094 | HP_0000520 | H05.20 | — | 2 | 2 | — | — | 2 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | 2 | 2 | — | — | 2 |
| Orbital diseases | D009916 | — | H05 | — | 2 | 2 | — | — | 2 |
| Adrenocortical carcinoma | D018268 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 2 | — | — | — | 7 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 2 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 2 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Linsitinib |
| INN | linsitinib |
| Description | 3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol is a member of quinolines and a member of cyclobutanes. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1 |
Identifiers
| PDB | — |
| CAS-ID | 1356958-77-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1091644 |
| ChEBI ID | — |
| PubChem CID | 11640390 |
| DrugBank | DB06075 |
| UNII ID | 15A52GPT8T (ChemIDplus, GSRS) |
Target
Agency Approved
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 943 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use